MedStar Washington Hospital Center Treats First COVID-19 Patient With Lenzilumab
MedStar Washington Hospital Center treated its first COVID-19 patient with study drug lenzilumab. MedStar Health is one of 18 sites participating in a Phase 3, multi-center clinical trial to assess whether the use of lenzilumab can alleviate the immune-mediated cytokine release syndrome and reduce the time to recovery in hospitalized patients with severe or critical COVID-19 pneumonia.
Fitbit App Receives Clinical Clearance Based on Clinical Trial Outcomes for Identifying Atrial Fibrillation
MedStar Health participated in a nationwide multi-site clinical trial, which studied Fitbit’s new electrocardiogram (ECG) app for assessing heart rhythm for atrial fibrillation. Fitbit has received 510(k) clearance from the FDA to use their ECG app to detect individual’s heart rhythm for signs of atrial fibrillation. The announcement was covered in Cardiac Rhythm News and mHealth Intelligence.
MEDSTAR HEALTH AWARDED R01 TO APPLY ARTIFICIAL INTELLIGENCE TO IMPROVE PATIENT SAFETY EVENT REPORTING AND ANALYSIS
MedStar Health National Center for Human Factors in Healthcare will be developing computational algorithms and software tools to make the reporting and analysis of patient safety event reports easier in order to improve patient safety. The four-year, $1.5 million R01 award is led by principal investigator Raj Ratwani, PhD. The research will focus on developing artificial intelligence and machine learning algorithms to classify medication related safety event reports into actionable medication error categories.
MedStar Health Awarded Grant to Implement and Evaluate Innovative Sepsis Clinical Decision Support
MedStar Health National Center for Human Factors in Healthcare was awarded a grant by The Society to Improve Diagnosis in Medicine as part of its DxQI Seed Grant Program. MedStar Health will use this grant to address sepsis, the most common cause of in-hospital death and the most expensive in-patient cost. the program will launch and evaluate a new sepsis-specific clinical decision support tool that uses a validated sepsis staging model to provide earlier and more accurate characterization of sepsis patients.
MedStar Health Selected by the AHRQ for Research Partner Network
MedStar Health is proud to announce its selection by the federal Agency for Healthcare Research and Quality (AHRQ) to participate in its research network, known as ACTION IV: Accelerating Change and Transformation in Organizations and Networks. Over the next 5 years, participation in the research network will allow MedStar Health to compete for contracts with an overall value up to $75 million.